CoChat

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To exploit this vulnerability, we developed a novel small-molecule inhibitor of the CBP/p300 bromodomain that blocks prostate cancer growth in vitro and in vivo. Molecular dissection of the consequences of drug treatment revealed a critical role for CBP/p300 in histone acetylation required for the transcriptional activity of the androgen receptor and its target gene expression. Our findings offer a preclinical proof of concept for small-molecule therapies to target the CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer. Cancer Res; 77(20); 5564–75. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-0314

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 49 references

Cited by

See all 153

Metadata

Authors
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., Ly, J., Choo, E., Kaufman, S., Beresini, M. H., Romero, F. A., Magnuson, S., & Gascoigne, K. E.
Affiliations
  • Genentech (US)
  • 2Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
  • Calico Life Sciences (US)
  • 8Unity Biotechnology, Brisbane, California.
Corresponding author
Gascoigne, Karen E.
Venue
Cancer Research
Published
2017-10-15
Volume
77
Issue
20
Pages
5564-5575
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2745907548
Cited by
153
References
49
Citations by year
2026: 8 · 2025: 16 · 2024: 26 · 2023: 16 · 2022: 14 · 2021: 20 · 2020: 16 · 2019: 22 · 2018: 11 · 2017: 3
FWCI
12.20
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
castration-resistant prostate cancer, CBP/p300, bromodomain inhibition, small molecule inhibitors, histone acetylation, androgen receptor, transcriptional coactivator, antiandrogen resistance, prostate cancer treatment
MeSH terms
Protein Domains, Animals, Female, Humans, Male, Random Allocation, Receptors, Androgen, Transfection, Signal Transduction, Gene Expression, Mice, SCID, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Growth Processes, E1A-Associated p300 Protein, Mice, Small Molecule Libraries, Gene Knockdown Techniques, Molecular Targeted Therapy, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0314
The paper
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., Ly, J., Choo, E., Kaufman, S., Beresini, M. H., Romero, F. A., Magnuson, S., & Gascoigne, K. E. (2017). Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.